Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
VYM Vanguard High Dividend Yield Index Fund ETF Shares
PG Procter & Gamble Co
LVS Las Vegas Sands Corp
AMP Ameriprise Financial Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
MRK Merck & Co Inc
HD Home Depot Inc
SQM Sociedad Quimica y Minera de Chile SA
AVGO Broadcom Inc
Go

Health Care : Biotechnology | Mid Cap Blend
Company profile

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Premarket

Last Trade
Delayed
$170.94
18.20 (11.92%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$152.74
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
326,064

10-day average volume:
30,518,247
326,064

MRNA's position in the Biotechnology industry

Industry PeersMRNAALNYBMRNSRPTIONS

Summary

Company ProfileModerna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines...
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics...
Go to ALNY summary
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's...
Go to BMRN summary
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare...
Go to SRPT summary
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs...
Go to IONS summary
52-Week Change

VS. INDUSTRY
650.20%
10.90%
-2.49%
25.22%
-21.00%
Market Cap

VS. INDUSTRY
$50.3B
$15.1B
$14.6B
$11.0B
$7.1B
Beta

VS. INDUSTRY
--
1.5
0.7
1.9
1.4
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
--
18.58x
--
103.60x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$246.7M
$401.0M
$1.9B
$495.1M
$932.7M
Profit Margin

VS. INDUSTRY
-242.27%
-222.19%
45.74%
-121.30%
6.29%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
202.43%
137.12%
16.22%
35.59%
13.60%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.